Archives: News

Mary Jane Geiger, M.D., Ph.D. Chief Medical Officer

Rita Shaw, PharmD Global Vice President, Regulatory Affairs

Ora Pescovitz, M.D. Independent Board Member

Angela Hecyk, B.S. Senior Clinical Project Manager

Kristi Schneider, MSN, RN, ANP-BC Senior Clinical Research Scientist

In the past several years, 67% of our placements are diverse, sought after talent.

Founded in San Francisco. Domann, in June 2023 we will be celebrating 35 years in the retained search business exclusively representing Life Science companies.

Our hires create immediate and long-term value for the client, investors and candidate.

We are pleased to share that the Domann Organization is celebrating 35 years in the retained executive search business serving the Life Sciences.

Thank you to all who have been part of our history improving the lives of many.

We look forward to continuing to build Life Science companies, creating value to our clients, their investors and the candidates we place who excel in their professions.

“the greatest achievement of the human spirit is to live up to one’s opportunities and make the most of one’s resources” Vauvenargues

Over the past 24 months we successfully completed key searches for the following private companies:

MBX Biosciences, (Independent Board Member, Chief Medical Officer, Global Vice President Regulatory)

Medikine, (President/Chief Medical Officer/Board Member)

Lengo Therapeutics, (Chief Medical Officer)

Estrigenix Therapeutics, (Executive Chair)

OnLume Surgical, (Chief Executive Officer)

ShouTi, (Senior Vice President, Biology)

Sardocor/Medera Bio (Vice President, Quality Operations, Vice President, Technical Operations)

Recent IPO public companies:

Inozyme Pharma (Senior Vice President, Technical Operations, Senior Vice President, Chief Medical Officer)

Oncolytics Biotech, (Chief Medical Officer, Executive Director, Clinical Operations, 

Executive Director, Translational Sciences, Medical Director, Clinical Development-Oncology)

Why Domann stands apart: Value creation for client, candidate, and investor. Name recognition, experience, knowledge of the Life Sciences community. Transparency, track record, network and trust.

It has been an active 24 months and we are looking forward to continuing building winning Life Science companies which make a major impact on people’s lives.

When considering search…consider Domann, Life Science leadership.

Bill Domann Email: bill@domann.net Jovanna Bost Email: jbost@domann.net 

Financing led by Wellington Management with participation from other leading healthcare funds.

CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the closing of a $115 million Series B financing. The Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed. In addition, Tiba Aynechi, Ph. D., general partner at Norwest Venture Partners, will join the MBX board.“MBX has grown tremendously as a company since closing our Series A two years ago, including bringing our lead program MBX 2109 into the clinic, achieving proof of mechanism and now starting the multiple ascending dose portion of our Phase 1 trial,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “With the support of these leading healthcare investors, we look forward to further advancing our Precision Endocrine Peptides as part of our goal to improve outcomes and quality of life for patients with endocrine disorders.”Proceeds of the financing will support MBX into early 2025 as it develops transformative therapeutics known as Precision Endocrine Peptides (PEPs™) designed to overcome limitations of traditional peptide therapeutics. This includes continued clinical advancement of its lead product candidate, MBX 2109, which is in development for the treatment of hypoparathyroidism and currently in a Phase 1 clinical trial. In addition, proceeds will support the company’s preclinical pipeline, led by MBX 1416, and discovery programs in endocrine diseases.“We are encouraged by the progress that MBX has made to date, including advancing its PEP therapeutic candidates and building a strong team to lead the organization into the future,” said Nilesh Kumar, Ph.D., Co-Head, Biotech Private Investment at Wellington Management. “We believe the company is well positioned to bring significant benefit to patients with endocrine disorders, and we are pleased to join a great investor syndicate in supporting the company.”About MBX BiosciencesMBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, NEA, OrbiMed, Wellington Management, RA Capital Management and Norwest Venture Partners. MBX is based in Carmel, Indiana.